Funding of the TNBC Initiative I3-STM
On the way to personalized immunotherapy against breast cancer – I3-STM receives ERDF NRW grant
Dortmund, September 2016 ++++
Taros Chemicals is participating in a new research venture, I3-STM, to develop an immunotherapeutic approach against triple-negative breast cancer (TNBC). This drug discovery initiative will take place over three years and is funded by the European Union and the state North Rhine-Westphalia. Througout this project, Taros will collaborate with various industrial and academic partners, including Syntab Therapeutics (Aachen), TECO Development (Rheinbach), Gremse-IT (Aachen) as well as the Institute of Laboratory Animal Science, the Institute for Experimental Molecular Imaging and the Medical Clinic III of the University Hospital Aachen.
The project focuses on producing a customized immunotherapeutic approach using synthetic drugs to combat TNBC. These drugs consist of components that stimulate the immune system and recognize tumor-specific marker molecules on the tumor parenchyma and the stroma. Futhermore, the search for biomarkers in the tumor parenchyma and stroma, as well as in the blood, enables the establishment of tailor-made drugs focusing on marker expression and immune activation for TNBC patients.
Taros will be the consortium partner in the synthesis of these sophisticated drug molecules using computer-aided drug design (CADD) and molecular modeling.
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
Acknowledgement of support
The project, titled “I3-STM”, has a duration of three years and is funded under the European Regional Development Fund (ERDF) by the state of North Rhine-Westphalia and the EU with approximately 3 million euros.
As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications
Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations, despite challenges, bridging very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project, starting from the development of synthetic routes to…